FDC Limited (FDC) Fair Value & Analysis
Healthcare · IN · Market cap ₹66.4B
Fair value as of: Jun 29, 2026
From 26 valuation models · updated yesterday
Share price +4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹310.52 – ₹488.73 · fair‑value band ₹143.95 – ₹374.13 · the ₹408.30 price screens above the ₹241.93 fair value. As of Jun 29, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
FDC Limited (FDC) currently trades at ₹408.30, while our model-based Fair Value estimate is ₹241.93 — implying the stock looks roughly 40.7% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, FDC Limited generated revenue of ₹21.7B at a net margin of 13.0%. Revenue grew 18.9% year over year. It earns a return on equity of 11.8%. The balance sheet holds a net cash position of ₹345M. Fundamentals as of Jun 29, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 29, 2026. TTM = trailing twelve months.
About the company
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
FDC Limited reported revenue of ₹21.7B in FY2026 versus ₹15.3B in FY2022, a compound +9.2%/yr. Reported net income was ₹2.8B in FY2026, compounding +6.8%/yr from FY2022.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is FDC Limited (FDC) undervalued?
What is the fair value of FDC?
What is the quality score of FDC?
What is the revenue of FDC Limited (FDC)?
What is the net profit margin of FDC?
Does FDC Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.